Picture of 23andMe Holding Co. logo

ME 23andMe Holding Co. Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-21.99%
3m+0.72%
6m-58.03%
1yr-78.81%
Volume Change (%)
10d/3m-44.26%
Price vs... (%)
52w High-79.14%
50d MA-12.16%
200d MA-39.77%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-254.43%
Return on Equity-147.75%
Operating Margin-310.27%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202531st Mar 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of 23andMe Holding Co. EPS forecast chart

Profile Summary

23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Directors

    Last Annual
    March 31st, 2024
    Last Interim
    March 31st, 2024
    Incorporated
    June 16th, 2021
    Public Since
    October 6th, 2020
    No. of Shareholders
    260
    No. of Employees
    560
    Sector
    Healthcare Providers & Services
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Capital Market
    Shares in Issue
    490,257,169

    ME Share Price Performance

    Upcoming Events for ME

    23andMe Holding Co. Annual Shareholders Meeting

    Similar to ME

    Picture of ADVANCED BIOMED logo

    ADVANCED BIOMED

    us flag iconNASDAQ Capital Market

    Picture of Akanda logo

    Akanda

    us flag iconNASDAQ Capital Market

    Picture of Assure Holdings logo

    Assure Holdings

    us flag iconNASDAQ Capital Market

    Picture of Astrana Health logo

    Astrana Health

    us flag iconNASDAQ Capital Market

    Picture of Avalon Globocare logo

    Avalon Globocare

    us flag iconNASDAQ Capital Market

    FAQ